DGIdb - OCTREOTIDE Drug Record

OCTREOTIDE chembl:CHEMBL1680 ApprovedAntineoplastic

Alternate Names:

SMS-995
SANDOSTATIN
SMS 201-995
SMS995
SMS-201-995
OCTREOTIDE

Drug Info:

Drug Class	hormone replacement agents
Drug Class	antineoplastic agents, hormonal
Year of Approval	1988
Drug Indications	antihypertensive agent
FDA Approval	approved
Drug Class	peptide
Drug Indications	antineoplastic agent
Drug Categories	cytochrome p-450 cyp3a inhibitors
Drug Categories	cytochrome p-450 cyp3a4 inhibitors
Drug Categories	cytochrome p-450 cyp3a4 inhibitors (strength unknown)
Drug Categories	cytochrome p-450 cyp3a4 inhibitors (weak)
Drug Categories	cytochrome p-450 enzyme inhibitors
Drug Categories	miscellaneous therapeutic agents
Drug Categories	potential qtc-prolonging agents
Drug Categories	qtc prolonging agents
Drug Categories	somatostatin receptor agonists

(4 More Sources)

Publications:

Wang et al., 2005, [Expression of somatostatin receptor reporter gene and its correlation with targeted imaging in vivo for detection of pancreas carcinoma]., Zhonghua Zhong Liu Za Zhi
Jaquet et al., 2005, BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide., J. Endocrinol. Invest.
Ruan et al., 2006, SOM230 inhibits insulin-like growth factor-I action in mammary gland development by pituitary independent mechanism: mediated through somatostatin subtype receptor 3?, Mol. Endocrinol.
Schmid et al., 2005, Short- and long-term effects of octreotide and SOM230 on GH, IGF-I, ACTH, corticosterone and ghrelin in rats., J. Endocrinol. Invest.
Matrone et al., 2004, Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs., Neuroendocrinology
John et al., 1996, Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2., Gut
Yim et al., 2009, Versatile conjugation of octreotide to dendrimers by cycloaddition ("click") chemistry to yield high-affinity multivalent cyclic Peptide dendrimers., Bioconjug. Chem.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Plöckinger et al., 2008, Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas., J. Clin. Endocrinol. Metab.
Shimon, 2003, Somatostatin receptors in pituitary and development of somatostatin receptor subtype-selective analogs., Endocrine
Theodoropoulou et al., 2006, Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression., Cancer Res.
Bronstein, 2006, Acromegaly: molecular expression of somatostatin receptor subtypes and treatment outcome., Front Horm Res
Xie et al., 2005, [Effect of HBV X gene transfection on octreotide-inhibited growth of hepatocellular carcinoma cell line HepG2]., Ai Zheng
Mimuro et al., 1998, The somatostatin analogue, octreotide, modifies both steroidogenesis and IGFBP-1 secretion in human luteinizing granulosa cells., Hum. Reprod.
Fredstorp et al., 1994, Inverse correlation between insulin-like growth factor binding protein-1 and insulin in patients with acromegaly during treatment with the somatostatin analogue octreotide., Clin. Endocrinol. (Oxf)
Sener et al., 2004, Octreotide ameliorates alendronate-induced gastric injury., Peptides
Verhelst et al., 1994, Octreotide in advanced prostatic cancer relapsing under hormonal treatment., Acta Urol Belg
Cervia et al., 2008, Modulation of the neuronal response to ischaemia by somatostatin analogues in wild-type and knock-out mouse retinas., J. Neurochem.
Kostoglou-Athanassiou et al., 2003, Scintigraphy with [111In]octreotide and 201Tl in a Hürthle cell thyroid carcinoma without detectable radio-iodine uptake. Report of a case and review of the literature., Horm. Res.

OCTREOTIDE SSTR1

Interaction Score: 3.28

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name CAM-2029

Novel drug target Established target

Trial Name oral octreotide actetate ,Octreolin

PMIDs:
16438887 16625841 16223973 16625842 15103227 8566856

Sources:
TdgClinicalTrial NCI TEND
OCTREOTIDE LPAR2

Interaction Score: 3.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18624922

Sources:
NCI
OCTREOTIDE SSTR5

Interaction Score: 2.52

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Specific Action of the Ligand Full agonist

Endogenous Drug? False

Trial Name CAM-2029

PMIDs:
16438887 16809928 16625841 16625842 16086874

Sources:
TdgClinicalTrial TEND GuideToPharmacology
OCTREOTIDE SSTR2

Interaction Score: 2.1

Interaction Types & Directionality:

binder

agonist (activating)

Interaction Info:

Specific Action of the Ligand Full agonist

Endogenous Drug? False

Direct Interaction? False

PMIDs:
19537708 11752352 18198230 12721506

Sources:
TdgClinicalTrial NCI GuideToPharmacology TTD
OCTREOTIDE IGFBP1

Interaction Score: 1.58

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9512248 7525123

Sources:
NCI
OCTREOTIDE TG

Interaction Score: 0.53

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14530610

Sources:
NCI
OCTREOTIDE KLK3

Interaction Score: 0.53

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
7515212

Sources:
NCI
OCTREOTIDE NF2

Interaction Score: 0.39

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Everolimus;Octreotide

Drug family MTOR inhibitor;Somatostatin analog

Alteration NF2:del

PMIDs:
None found

Sources:
CGI
OCTREOTIDE SSTR3

Interaction Score: 0.36

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Specific Action of the Ligand Full agonist

Endogenous Drug? False

PMIDs:
None found

Sources:
GuideToPharmacology
OCTREOTIDE MPO

Interaction Score: 0.36

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15003363

Sources:
NCI
OCTREOTIDE PIK3CB

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16452215

Sources:
NCI
OCTREOTIDE PIK3CG

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16452215

Sources:
NCI

DrugBank: DB00104

Version: 5.1.7

Alternate Names:

OCTREOTIDE DrugBank Drug Name

83150-76-9 CAS Number

BYNFEZIA Pen Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Groups investigational

Publications:

Casarini AP et al., 2009, Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment., Pituitary

Mulak A et al., 2015, Selective agonists of somatostatin receptor subtype 1 or 2 injected peripherally induce antihyperalgesic effect in two models of visceral hypersensitivity in mice., Peptides

TEND: OCTREOTIDE
- Version: 01-August-2011
Alternate Names:

OCTREOTIDE Primary Drug Name

Drug Info:

Year of Approval 1988

Drug Class antineoplastic agents, hormonal

Drug Class hormone replacement agents

Publications:
TdgClinicalTrial: OCTREOTIDE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class peptide

FDA Approval approved

Publications:

NCI: OCTREOTIDE

Version: 14-September-2017

Alternate Names:

C711 NCI drug code

Drug Info:

Publications:

Verhelst et al., 1994, Octreotide in advanced prostatic cancer relapsing under hormonal treatment., Acta Urol Belg

Shimon, 2003, Somatostatin receptors in pituitary and development of somatostatin receptor subtype-selective analogs., Endocrine

Plöckinger et al., 2008, Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas., J. Clin. Endocrinol. Metab.

TTD: Octreotide
- Version: 2020.06.01
Alternate Names:

D02XIY TTD Drug ID

Drug Info:

Publications:
GuideToPharmacology: 135652471
- Version: 29-September-2020
Alternate Names:

OCTREOTIDE GuideToPharmacology Ligand Name

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1680
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
CGI: Octreotide
- Version: 27-September-2017
Alternate Names:

Drug Info:

Publications:

Trial Name	CAM-2029
Novel drug target	Established target
Trial Name	oral octreotide actetate ,Octreolin

Specific Action of the Ligand	Full agonist
Endogenous Drug?	False
Trial Name	CAM-2029

combination therapy	Everolimus;Octreotide
Drug family	MTOR inhibitor;Somatostatin analog
Alteration	NF2:del

OCTREOTIDE	DrugBank Drug Name
83150-76-9	CAS Number
BYNFEZIA Pen	Drug Brand

Drug Type	small molecule
Drug Groups	approved
Drug Groups	investigational

binder
agonist (activating)

OCTREOTIDE Drug Record

OCTREOTIDE chembl:CHEMBL1680 ApprovedAntineoplastic

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info: Trial Name CAM-2029 Novel drug target Established target Trial Name oral octreotide actetate ,Octreolin

PMIDs: 16438887 16625841 16223973 16625842 15103227 8566856

Sources: TdgClinicalTrial NCI TEND

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18624922

Sources: NCI

Interaction Types & Directionality: agonist (activating)

Interaction Info: Specific Action of the Ligand Full agonist Endogenous Drug? False Trial Name CAM-2029

PMIDs: 16438887 16809928 16625841 16625842 16086874

Sources: TdgClinicalTrial TEND GuideToPharmacology

Interaction Types & Directionality: binder agonist (activating)

Interaction Info: Specific Action of the Ligand Full agonist Endogenous Drug? False Direct Interaction? False

PMIDs: 19537708 11752352 18198230 12721506

Sources: TdgClinicalTrial NCI GuideToPharmacology TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9512248 7525123

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 14530610

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 7515212

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Everolimus;Octreotide Drug family MTOR inhibitor;Somatostatin analog Alteration NF2:del

PMIDs: None found

Sources: CGI

Interaction Types & Directionality: agonist (activating)

Interaction Info: Specific Action of the Ligand Full agonist Endogenous Drug? False

PMIDs: None found

Sources: GuideToPharmacology

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15003363

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16452215

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16452215

Sources: NCI

DrugBank: DB00104

Alternate Names: OCTREOTIDE DrugBank Drug Name 83150-76-9 CAS Number BYNFEZIA Pen Drug Brand

Drug Info: Drug Type small molecule Drug Groups approved Drug Groups investigational

TEND: OCTREOTIDE

Alternate Names: OCTREOTIDE Primary Drug Name

Drug Info: Year of Approval 1988 Drug Class antineoplastic agents, hormonal Drug Class hormone replacement agents

Publications:

TdgClinicalTrial: OCTREOTIDE

Alternate Names:

Drug Info: Drug Indications antineoplastic agent Drug Class peptide FDA Approval approved

Publications:

NCI: OCTREOTIDE

Alternate Names: C711 NCI drug code

Drug Info:

TTD: Octreotide

Alternate Names: D02XIY TTD Drug ID

Drug Info:

Publications:

GuideToPharmacology: 135652471

Alternate Names: OCTREOTIDE GuideToPharmacology Ligand Name

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL1680

Alternate Names:

Drug Info:

Publications:

CGI: Octreotide

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name CAM-2029

Novel drug target Established target

Trial Name oral octreotide actetate ,Octreolin

PMIDs:
16438887 16625841 16223973 16625842 15103227 8566856

Sources:
TdgClinicalTrial NCI TEND

Interaction Types & Directionality:

n/a

PMIDs:
18624922

Sources:
NCI

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Specific Action of the Ligand Full agonist

Endogenous Drug? False

Trial Name CAM-2029

PMIDs:
16438887 16809928 16625841 16625842 16086874

Sources:
TdgClinicalTrial TEND GuideToPharmacology

Interaction Types & Directionality:

binder

agonist (activating)

Interaction Info:

Specific Action of the Ligand Full agonist

Endogenous Drug? False

Direct Interaction? False

PMIDs:
19537708 11752352 18198230 12721506

Sources:
TdgClinicalTrial NCI GuideToPharmacology TTD

Interaction Types & Directionality:

n/a

PMIDs:
9512248 7525123

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
14530610

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
7515212

Sources:
NCI

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Everolimus;Octreotide

Drug family MTOR inhibitor;Somatostatin analog

Alteration NF2:del

PMIDs:
None found

Sources:
CGI

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Specific Action of the Ligand Full agonist

Endogenous Drug? False

PMIDs:
None found

Sources:
GuideToPharmacology

Interaction Types & Directionality:

n/a

PMIDs:
15003363

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
16452215

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
16452215

Sources:
NCI

Alternate Names:

OCTREOTIDE DrugBank Drug Name

83150-76-9 CAS Number

BYNFEZIA Pen Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Groups investigational

Alternate Names:

OCTREOTIDE Primary Drug Name

Drug Info:

Year of Approval 1988

Drug Class antineoplastic agents, hormonal

Drug Class hormone replacement agents

Drug Info:

Drug Indications antineoplastic agent

Drug Class peptide

FDA Approval approved

Alternate Names:

C711 NCI drug code

Alternate Names:

D02XIY TTD Drug ID

Alternate Names:

OCTREOTIDE GuideToPharmacology Ligand Name